1999
DOI: 10.1038/sj.bjp.0702392
|View full text |Cite
|
Sign up to set email alerts
|

Prostanoid receptors involved in the relaxation of human bronchial preparations

Abstract: 1 Iloprost and cicaprost (IP-receptor agonists) induced relaxations in the histamine-(50 mM) contracted human bronchial preparations (pD 2 values, 6.63+0.12 and 6.86+0.08; E max values, 90+04 and 65+08% of the papaverine response for iloprost (n=6) and cicaprost (n=3), respectively).2 Prostaglandin E 2 (PGE 2 ) and misoprostol (EP-receptor agonist) relaxed the histamine-contracted human bronchial preparations (pD 2 values, 7.13+0.07 and 6.33+0.28; E max values, 67+04 and 57+08% of the papaverine response for P… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
55
2
1

Year Published

2001
2001
2023
2023

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 81 publications
(64 citation statements)
references
References 30 publications
6
55
2
1
Order By: Relevance
“…Thus, there appears to be a PGI 2 deficiency in emphysematous COPD and a reciprocal increase in TXA 2 generation with predicted undesirable effects on platelet reactivity and pulmonary vascular smooth muscle function. Clearly, a selective IP-receptor agonist could restore this PGI 2 /TXA 2 imbalance and, thereby, reduce the threshold for platelet aggregation (71), lower pulmonary vascular resistance (72) (through smooth muscle relaxation and, long term, by inhibiting mitogenesis), and even promote bronchodilatation (73). The results of this study indicate that an IP-receptor agonist could also suppress airway and pulmonary vascular inflammation by enhancing the clinical efficacy of an ICS.…”
Section: Targeting the Ip-receptor In Copdmentioning
confidence: 64%
“…Thus, there appears to be a PGI 2 deficiency in emphysematous COPD and a reciprocal increase in TXA 2 generation with predicted undesirable effects on platelet reactivity and pulmonary vascular smooth muscle function. Clearly, a selective IP-receptor agonist could restore this PGI 2 /TXA 2 imbalance and, thereby, reduce the threshold for platelet aggregation (71), lower pulmonary vascular resistance (72) (through smooth muscle relaxation and, long term, by inhibiting mitogenesis), and even promote bronchodilatation (73). The results of this study indicate that an IP-receptor agonist could also suppress airway and pulmonary vascular inflammation by enhancing the clinical efficacy of an ICS.…”
Section: Targeting the Ip-receptor In Copdmentioning
confidence: 64%
“…Inhibitory Effects of AH6809 on Contraction in Isolated Gastric Fundus of Rats 12,13) The experiment was carried out using Magnus method. 14) Male Sprague-Dawley rats were fasted for about 16 h and killed by exsanguination.…”
Section: )mentioning
confidence: 99%
“…PGE 2 has 4 receptor subtypes (EP 1-4 receptors), whereas PGs D 2 , F 2␣ , I 2 , and thromboxane (TX) A 2 each have a single receptor (DP, FP, IP, and TP receptors, respectively). 1 The DP receptor is coupled positively to adenylyl cyclase through G s , 1 and this results in a strong inhibitory effect on platelet aggregation 2 as well as bronchodilator 3 and vasodilator 4 effects in humans. The DP receptor and lipocalin-type PGD synthase are both abundant in the central nervous system, where PGD 2 plays a role in regulating sleep 5 and pain perception.…”
Section: Introductionmentioning
confidence: 99%